KIMIA
chemistry of well being

Ref: KIMIABL/CS/2026-27/030 Date- 13.11.2026

To
Department of Corporate Affairs- Listing
BSE Limited
PhirozJeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]
ISIN: INE285U01025

Sub: Outcome of Board Meeting held on November 13, 2026 (Friday)

Dear Sir,
Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have enclosed herewith:

1. Unaudited Standalone Financial Results of the Company for the Second quarter and half year ended September 30, 2026, including the Statement of Assets and Liabilities, Statement of Profit and Loss and Statement of Cash Flows, has inter alia duly approved and taken on record by the Board of Directors at their meeting held today i.e. Friday, November 13, 2026; &
2. Limited Review Report on the aforesaid results from Statutory Auditors of the Company, M/s NEERAJ ARORA AND ASSOCIATES Chartered Accountants (FRN: 021309N) as placed before the Board of Directors of the Company in its meeting held today.

The report of the Auditors is with unmodified opinion with respect to the Financial Results. The above shall also be made available on the website of the Company at www.kimiabiosciences.com The Board Meeting commenced at 04:00 p.m. and concluded at 4.30 p.m.

Kindly take the above information on your records.

Thanking You,
For **KIMIA BIOSCIENCES LIMITED**

KIMIA BIOSCIENCES LIMITED NEW DELHI

ABHISHEK KUMAR PANDEY
(COMPANY SECRETARY & COMPLIANCE OFFICER)
M.NO F12457
PLACE: DELHI
ENCL.: A/A

Neeraj Arora & Associates
Chartered Accountants

CA Neeraj Kumar Arora
M: +91 9911099977
E: neerajaroraassociates@gmail.com

Review Report

To
The Board of Directors
Kimia Biosciences Limited
Village Bhondsi, Tehsil Sohna
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended September 30, 2026 (the "Statement") and year to date results for the period from April 01, 2026 to September 30, 2026, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

3. Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Neeraj Arora & Associates
FRN: 021309N

Neeraj Kumar Arora
M. No. 510750
UDIN: - **26510750GRVJBA6840**
Place: - Gurugram
Dated: - November 13, 2026

KIMIA BIOSCIENCES LIMITED
(Formerly known as Laurel Organics Limited)
Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102
Phone: +91 9654746544, 9654206544 Email: compliance.kimiabiosciences@gmail.com & info@kimiabiosciences.com
Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Half Year Ended		Year Ended
		30/09/2026 (Unaudited)	30/06/2026 (Unaudited)	30/09/2025 (Unaudited)	30/09/2026 (Unaudited)	30/09/2025 (Unaudited)	31/03/2026 (Audited)
I	Revenue from Operations	2,681.19	2,072.25	3,399.93	4,753.44	5,758.34	11,488.38
II	Other Income	(0.41)	8.06	(33.17)	7.65	51.52	162.17
III	Total Income (I+II)	2,680.78	2,080.31	3,366.76	4,761.09	5,809.86	11,650.55
IV	Expenses:				-		
	a) Cost of materials consumed	1,094.87	1,656.68	1,771.04	2,751.55	3,477.23	6,565.79
	b) Change in inventories of finishe	407.14	(533.54)	474.77	(126.40)	184.45	446.09
	c) Employee benefits expenses	291.40	296.97	330.83	588.37	658.50	1,261.61
	d) Finance costs	104.85	83.05	26.70	187.90	201.41	351.57
	e) Depreciation and amortisation e	112.91	110.74	97.13	223.65	190.66	391.32
	f) Other expenses	429.91	417.43	571.29	847.34	933.47	1,788.16
V	Total Expenses (IV)	2,441.08	2,031.33	3,271.76	4,472.41	5,645.72	10,804.54
VI	Profit/(loss) before exceptional iten	239.70	48.98	95.00	288.68	164.14	846.01
VII	Exceptional Items	-	-	-	-	-	-
VI	Profit/(loss) before tax (IV-V)	239.70	48.98	95.00	288.68	164.14	846.01
VII	Tax expenses:						
	a) Current Tax	-	-	-	-	-	-
	b) Current Tax related to earlier y	-	-	-	-		-
	b) Deferred Tax charge / (credit)	0.94	13.40	(6.51)	14.34	2.23	102.64
VIII	Profit/(loss) for the period (VI-VII	238.76	35.58	101.51	274.34	161.91	743.37
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
	- Remeasurement of defined benefit plans	-	-	-	-	-	42.85
B.	Items that will be reclassified to Pr	-	-	-	-	-	(10.78)
X	Total Comprehensive Income for the period (VIII+IX)	238.76	35.58	101.51	274.34	161.91	775.44
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
	b. Paid up debt capital (Instruments entirely equity in nature (CCPS))	-		-			
	c. Paid up debt capital (Redeemable Non-Convertible Cumulative Preference Shares)						
XII	Other Equity						
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	0.50	0.08	0.21	0.58	0.34	1.64
	Diluted in Rs.	0.50	0.08	0.21	0.58	0.34	1.64

FOR KIMIA BIOSCIENCES LIMITED

Manjeer Goel
(Managing Director & CEO)
DIN - 00161786

Date: November 13, 2026
Place: New Delhi

KIMIA BIOSCIENCES LIMITED NEW DELHI

KIMIA BIOSCIENCES LIMITED
(Formerly known as Laurel Organics Limited)
Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102
Phone: +91 9654746544, 9654206544 Email: compliance.kimiabiosciences@gmail.com & info@kimiabiosciences.com
Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

AUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER AND YEAR ENDED September 30, 2026

STATEMENT OF ASSETS, EQUITY and LIABILITIES

S. No.	Particulars	As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
A	ASSETS		
1	Non-Current Assets		
	Property, Plant & Equipment	2,894.37	3,007.70
	Capital Work-in-Progress	-	16.90
	Right of Use Assets	12.32	14.96
	Intangible Assets	792.35	709.92
	Financial Assets		
	(i) Other Non Current Financial Assets	63.99	44.25
	Deferred Tax Assets (Net)	48.49	62.83
	Other Non-current Assets	108.66	101.14
2	Current Assets		
	Inventories	3,505.94	2,625.82
	Financial Assets		
	(i) Investment	-	-
	(ii) Trade Receivables	2,283.14	2,932.00
	(iii) Cash and Cash Equivalents	27.05	31.58
	(iv) Bank balances other than	50.42	50.42
	(iii) above		
	(v) Other Current Financial	113.46	55.59
	Assets		
	Current Tax Assets (Net)	80.92	75.57
	Other Assets	771.75	591.05
	Total Assets	10,752.86	10,319.73

S. No.	Particulars	As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
B	EQUITY & LIABILITIES		
1	EQUITY		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	1,573.26	1,298.92
2	NON CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2,767.02	2,280.89
	(ii) Lease Liabilities	4.93	4.93
	(iii) Other financial liabilities	-	-
	Provisions	179.26	143.49
	Other Non-Current Liabilities	-	-
3	CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2,231.16	1,181.90
	(ii) Lease Liabilities	8.32	10.81
	(iii) Trade Payables	-	-
	a. Total Outstanding due to Micro and Small Enterprises	14.86	6.18
	b. Total Outstanding due to other than Micro and Small	2,993.50	4,215.27
	(iii) Other Financial Liabilities	93.48	295.47
	Other Current Liabilities	413.94	405.58
	Provisions	-	3.16
	Total Equity and Liabilities	10,752.86	10,319.73

FOR KIMIA BIOSCIENCES LIMITED

Sameer Goel
(Managing Director & CEO)
DIN - 00161786

Date: November 13, 2026
Place: New Delhi

KIMIA BIOSCIENCES LIMITED NEW DELHI

KIMIA BIOSCIENCES LIMITED
(Formerly known as Laurel Organics Limited)
Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102
Phone: +91 9654746544, 9654206544 Email: compliance.kimiabiosciences@gmail.com & info@kimiabiosciences.com
Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

STATEMENT OF CASH FLOWS

	Particulars	For the half year ended 30-09-2026 (Unaudited)	For the half year ended 30-09-2025 (Unaudited)
A.	Cash Flow from Operating Activities		
	Net Profit / (Loss) before tax	288.68	164.14
	Adjustment for :		
	Depreciation and amortization expense	223.65	190.66
	Finance costs	187.90	201.41
	Gain on fair value of investment in mutual funds	-	-
	Interest income	(1.30)	(2.61)
	Deferred revenue income	-	-
	Unrealised (gain)/loss on foreign currency transactions and translations	-	-
	Operating Profit Before Working Capital Changes	410.25	553.60
	Adjustments for:		
	(Increase)/ Decrease in inventories	(880.12)	(6.91)
	(Increase)/ Decrease in trade and other receivables	384.33	993.49
	Increase/ (Decrease) in trade and other payables	(1,069.63)	(1,405.30)
	Increase/ (Decrease) in Lease Liabilities	(2.49)	(8.94)
	Cash Generated From Operations	(1,157.66)	125.94
	Less : Income tax paid/ (refunds)	(5.35)	(1.83)
	Net Cash From Operating Activities	(1,163.01)	124.11
B.	Cash Flow from Investment Activities		
	Purchases of property, plant and equipments including intangible assets & capital advances	(173.21)	(202.70)
	Net inflow / (outflow) in fixed deposits	-	(2.60)
	Purchase of current investments	-	
	Interest received	-	2.61
	Net Cash Used In Investing Activities	(173.21)	(202.69)
C.	Cash Flow from Financing Activities		
	Receipts from non current borrowings	540.36	547.15
	Repayment of non current borrowings	(54.23)	45.84
	Net proceeds of current borrowings	1,049.26	(278.66)
	Finance costs paid	(492.38)	(235.39)
	Net Cash Used in Financing Activities	1,043.01	78.94
	Net Increase/(Decrease) in Cash and Cash Equivalents	(4.53)	0.36
	Cash and Cash Equivalents at the beginning of the period	31.58	20.61
	Cash and Cash Equivalents at the end of the period	27.05	20.97

Other Notes

1	The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
2	The above results have been reviewed by Audit Committee and Approved by the Board of Directors of the Company at their respective meetings held on November 13, 2026.

FOR KIMIA BIOSCIENCES LIMITED

Sameer Goel
(Managing Director & CEO)
DIN - 00161786

Date: November 13, 2026
Place: New Delhi

KIMIA BIOSCIENCES LIMITED NEW DELHI

KIMIA
chemistry of well being

CERTIFICATE PURSUANT TO REGULATION 33(2)(a) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

We, Sameer Goel, (Managing Director & CEO) and Mani Jain, (Chief Financial Officer), of the Company hereby certify that the Un-audited Financial Results for the Second quarter and half year ended on September 30, 2026 as placed before the Board of Directors do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

SAMEER GOEL
(Managing Director & CEO)
DIN-00161786

MANI JAIN
(Chief Financial Officer)

Date: 13-11-2026
Place: New Delhi

KIMIA BIOSCIENCES LIMITED
Regd. Office/Works:
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana-122102
Tel.: +91 9654746544, 9654206544

Corporate Office:
974, 9th Floor, Aggarwal Millennium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel: +91 11 47063600, 47063601

compliance.kimiabiosciences@gmail.com I www.kimiabiosciences.com I CIN No: L24239HR1993PLC032120